Nanobiotechnology

Published by: Global Industry Analysts

Published: Jun. 1, 2006 - 321 Pages

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

II. EXECUTIVE SUMMARY

1. Industry Overview

A Curtain Raiser

What’s The Obsession With Size?

Why Analysis at the Cellular Level is Important?

Lessons from Nature

Where Conventional Molecular Science Falls Short Nanobio Steps In

Conclusions

Dawn Breaks On Nanobiotechnology

Demystifying the Intriguing World of Nanobiotech

Nanoparticles: The Foundation of Nanobiotechnology

A Meeting Place of Medicine’s Best Solutions

Challenges

Nanotechnology Boom Echoes Downstream

Honey, I Shrunk the World!

Nanotechnology & Biology Tie the Knot: “Two to Tango”

Nanobiotechnology: The Next Battlefield

The Promise of Nanobiotechnology

Biological Weaponries Against Diseases Come in Small Packages

Proffered Benefits of Nanobiotechnology

Opportunity & Beyond

Nanobiotechnology - Will it Live Up to the Expectations?

The Future of Nanobiotechnology: Shape of Things to Come

Nanobiotechnology: The Outer Limits

Futuristics: A Rumination

Nanobiotechnology In the Year 2015

Field of Nanodiagnostics

Field of Regenerative Medicine

Field of Targeted Drug Delivery

2. Market Dynamics

Short Market Sizzlers

Consolidation to Speed Up in Nano-Enabled Delivery Systems Market

Dearth of Blockbuster Drugs in Pipeline Sparks Interest in Nanobio

Demand for Novel Products Complements the Exuberant Outlook

Public & Private Investment Pep Up the Market

The Regulatory Framework Evolves with the Technology

Nanomaterials & Nanoparticles Witness Robust Activity

Quantum Dot Patents Pose Legal Tangles

Colloidal Quantum Dots Prices Poised to Scale Down in Long Run

Miniaturized Liquid Handling Becomes Progressive

Unrealistic Expectations Exert Pressure On the Market

High Material Costs Put a Spoke in the Market’s Growth

Below Par Involvement from Pharma Biggies Limits Growth

Lack of De Facto Standards: A Challenge to Reckon With

Loosely Defined Safety Standards Creates a Niggling Worry

3. Industry Issues, Challenges & Controversies

Embroilment Over Ethical Issues

Social Relevance

Economic Relevance

Major Challenges Confronting the Industry

Commercial Exploration: A Treacherous Voyage

Dendrimers Commercialization - An Uphill Task

High Production Costs and Development Complexity

Availability of Advanced Technology Alternatives

No Defined Framework to Judge New Product’s Safety and Efficacy

4. Industry Structure & Investment Patterns

Industry Structure: A Quick Primer

A Dissection of Select Segments

Nanoparticles

Nanotubes and Fullerenes

Dendrimers

A Peek Into the Regulatory Framework

United States

Europe

What’s Grooming Nanobiotech into an Investment High Street?

Interest Ignited by Nanotechnology

Tracking Investment Patterns in Nanobiotechnology

Interest in Nanobiotechnology Spills Over

Patent Expiration Sends the Popularity Index Spiraling

Drawing Significant Venture Capital Funds

Table 1: Venture Capital Funding in Nanobiotechnology as Compared to Other Types of Nanotechnology: A Peek into Substantiating Numerics Taking the US Market as a Demonstrative Example

Swelling Government Grants

The State of Public Sector Funding

Table 2: Nanobiotechnology Market in Select Regions (2004): Percentage Breakdown of Public Sector Funding by Country - South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart)

A Closer Look at Regional Nano Efforts

United States: Unraveling the Country’s Edge

Europe: Hot On the Heels of the US

Germany

France

United Kingdom

Scandinavia

Table 3: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country - European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart)

Japan: A Noteworthy Region

5. Nanobio’s Epochal Strides In Modern Medicine

A Primer

Impact on Drug Delivery Systems

Benefits Offered

Drug Encapsulation

High Level of Specificity

Increase in Drug Solubility and Uptake

Greater Usage Flexibility

Impact On Molecular Diagnostic Imaging

Seeing The Unseen

Impact On Pharmaceutical Drug Formulations

Impact On Therapeutics

Silver Nanoparticles as Effective Antimicrobial Agents

Modern Day Nanomedicine: A Current Scenario

Nanomedicine: The Cynosure of All Eyes

Drug Delivery Systems Epitomized by Nanomedicine

Targeted NanoDrug Delivery & Release

A Peek Into Potential Nanobio Enabled Drug Carriers

Micelles

Liposomes

Dendrimers & Liquid Crystals

Nanoparticles

Polymeric Nanoparticles

Hydrogels

Molecularly Imprinted Polymers

Microelectromechanical Systems (MEMS)

Nanosuspensions

Fullerenes: A Platform for GenX Drug Delivery

Types of Nano-Based Drug Delivery Systems, Related Materials, and Structures

Dynamics of Regenerative Medicine

Tissue Engineering and Restorations

Nanotechnology Enabled Diagnostics

Promised Path Breaking Applications in Molecular Diagnostics & Imaging

In-Vitro Diagnostics

In-Vivo Diagnostics

Nanoprobes & Implantable Devices in In-vivo Imaging

Nanocomposites in Molecular Labeling & Diagnostics

Laboratory-on-a-Chip - A Revolutionary Technology in Biomolecular Detection

Biosensors - Heralding New Opportunities in Molecular Diagnostics

Despite Huge Potential Key Hurdles Remain in Commercialization

Magnetic Nanoparticles for Imaging Applications in MRI

Dendrimers Promise Milestone Applications in MRI

Conclusions

Gauging the Real World Impact of Nanobiotech On Cancer: A Case Study

Quantum Dots Cock a Snook at Traditional Anti-Body Labeling Agents

Chemotherapeutic Reengineering & Gene Therapy: New Treatment Regimes

Laboratory-on-chip (LOC): A Platform for Cancer Diagnosis

6. Technology Overview

Nanotechnology: An Introduction

A Revolution in the Making

Nanobiotechnology: An Exposition

Nanobiotechnology & Medicine

Nanobiotechnology & Biofuels

Global Nanobiotechnology Market (2005): Major Products

Global Nanobiotechnology Market (2005): Major Products Under Development

Analysis of Major Technology Segments

Nanomaterials

Nanoparticles

Nanoparticles in Labeling or Bio Tagging

Nanoparticles as Biomarkers

Classification of Nanoparticles

Solid Nanoparticles

Solid Lipid Nanoparticles

Calcium Phosphate Nanoparticles

Dendrimers

Dendrimers as Templates for Synthesis of Hybrid Nanostructures

Nanocomposites

Lamellar Nanocomposites

Nanostructured Materials and Membranes

Nanotubes and Fullerenes

Other Nanomaterials

Nanoshells

Nanohorns

Nanocapsules

Nanodevices

Nanotools

Select Nanotools

Atomic Force Microscopes

Hot Embossing Lithography

Dip-Pen Nanolithography

7. Global Research Centers and Institutions

Centre for Biologic Nanotechnology (USA)

Centre for Biological and Environmental Nanotechnology (USA)

Institute of Bioengineering and Nanotechnology (Singapore)

The Nanobiotechnology Center (USA)

The Tyndall National Institute (Ireland)

8. Research & Technology Effervescence

Dendritic NanoTechnologies Develops Novel Priostar™ Dendrimer Technology

Scientists Develop Novel DNA Buckyballs for Drug Delivery Applications

Nanotechnology Creates Hopes for Artificial Kidneys

Chinese Scientists Develop Novel Drug Delivery System

Scientists Attach Nanograins to Iron Oxide Nanoparticles for Drug Delivery

Researchers Employ Nanotubules to Diffuse Cancer Cells

Scientists Develop Innovative Nanoparticles for Cancer Treatment

Nanobiotech Companies Close in on Developing Avian Flu Vaccine

Silver Nanoparticles Show Promise Against H

Virus

Nanoparticles Prove Highly Active Against Water Contaminants

Nanobiotechnology Offers Major Breakthrough in New HIV Drug Development

Scientists Develop Innovative Nanoparticles to Treat Tumors

Nano-sized Polymers Offer Key Application in Treating Tumor Cells

Carbon Nanotubes Hold Promise in Development of Synthetic Muscular Tissues

Silicon Nanowires Offer Key Solutions to Cancer Detection and Diagnosis

Antigen Loaded Nanospheres Induce Immune Response

Triton's Nanotechnology Promises Potential Tool against Tumors

Carbon Nanotubes for Development of Advanced Biosensors

Scientists Develop New Technology to Produce Gold and Silver Nanoparticles

Scientists Develop Optical Biosensors from Single- Walled Carbon Nanotubes

Layer-by-Layer Nanoassembly Method for Nanocapsule Synthesis Gets Underway

Nanowires Prove Effective in Viruses Detection

Nanobiotechnology Enables SARS Test Development

9. Product Introductions/Developments

Evident Technologies Introduces Metal Quantum Dot Reagents

Abraxis Oncology Launches Novel Abraxane Drug Delivery System

Nanophase Introduces Novel Zinc Oxide Nanomaterial

ANP Technologies Develops Innovative Biological Detection System

Acrongenomics Introduces Innovative Cancer Detection Equipment

10.Recent Industry Activity

Invitrogen Acquires Quantum Dot Corporation

NABsys and Brown University Forge Partnership

University of Maryland Forges Partnership with University of Maryland Biotechnology Institute

ANP Technologies Partners with Cogent Systems

NCI forms Strategic Partnership with NSF

Debiopharm and Nanocarrier Ink Pact to Develop Platinum Anti Cancer Product

Capsulution and Ebara Sign Manufacturing Agreement for Nano- capsules

Invitrogen Licenses Nanoclusters Technology from Georgia Tech Research

Dendritic NanoTechnologies, Starpharma, and Dow Ink Pact

Dendritic Nanotechnologies Inks Collaboration Pact with NCL

Flamel Terminates Licensing Agreement with Biovail

MFIC Corporation and University of Massachusetts Sign Collaboration Pact

TAP Delivers Notice to Terminate Licensing Agreement with Flamel

Nanophase Inks Pact with Competitive Technologies

Infectech Changes Name to Nanologix

Arrowhead Establishes Nanobiotechnology Company

NCI Grants Funds to Establish Centers of Cancer Nanotechnology Excellence

Capsulution Bags Patents to Develop and Market Nano and Microstructures

Capsulution Receives Patent for Production of Novel Nano and Micro-Capsules

Carbon Nanotechnologies Wins 30 Patents for Small-diameter Carbon Nanotubes

Adnavance Technologies Receives Funding for M-DNA Technology

Angstrom Medica Wins FDA Approval for Nanoss™ Bone Void Filler

Carbon Nanotechnologies and C Sixty Merge

Capsulution and Nanosolutions to Join Forces

UK Institutions Forge Partnership to Develop Novel Therapy for Cancer

Triton and XOMA Sign Licensing Agreement

BioTrove Receives $11.1Million Funding to Develop Nanobiotechnology Products

Alnis Secures $2.71 Million Funding from NCI

Invitrogen Acquires Genicon's RLS Technology

C Sixty Inks License, Option and Supply Agreement with Merck.

Alnis Wins Health Contract Award from NCI

11.Focus on Select Global Players

Alnis Biosciences, Inc. (USA)

American Pharmaceutical Partners, Inc. (USA)

Biosante Phosphate Pharmaceuticals, Inc. (USA)

Capsulution NanoScience AG (Germany)

Carbon Nanotechnologies, Inc. (USA)

C Sixty, Inc. (USA)

Dendritic Nanotechnologies, Inc. (USA)

Dendritech, Inc. (USA)

Elan Pharmaceuticals (USA)

Flamel Technologies, Inc. (France)

iMedd, Inc. (USA)

Nanospectra Biosciences, Inc. (USA)

Nanophase Technologies Corporation (USA)

Nano-C, Inc. (USA)

Nanocyl SA (Belgium)

Nanolab Systems Ltd. (Finland)

Nanosphere, Inc. (USA)

Nanotherapeutics, Inc. (USA)

Nanosys, Inc. (USA)

PSiVida Ltd (Australia)

Quantum Dot Corp. (USA)

Starpharma Holdings Ltd. (Australia)

Sigma Aldrich Company (USA)

Triton Biosystems, Inc (USA)

12.Global Market Perspective

Table 4: World Recent Past, Current & Future Analysis for Nanobiotechnology by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 5: World 10-Year Perspective for Nanobiotechnology by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 6: World Recent Past, Current & Future Analysis for Nanomaterials by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 7: World 10-Year Perspective for Nanomaterials by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 8: World Recent Past, Current & Future Analysis for Solid Inorganic Nanoparticles by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010(includes corresponding Graph/Chart)

Table 9: World 10-Year Perspective for Solid Inorganic Nanoparticles by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 10: World Recent Past, Current & Future Analysis for Nanocomposites by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 11: World 10-Year Perspective for Nanocomposites by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 12: World Recent Past, Current & Future Analysis for Nanostructured Materials & Membranes by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 13: World 10-Year Perspective for Nanostructured Materials & Membranes by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 14: World Recent Past, Current & Future Analysis for Nanotubes and Fullerenes by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 15: World 10-Year Perspective for Nanotubes and Fullerenes by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 16: World Recent Past, Current & Future Analysis for Other Nanomaterials by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 17: World 10-Year Perspective for Other Nanomaterials by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

Table 18: World Recent Past, Current & Future Analysis for Nanodevices/Tools by Geographic Region - USA, Japan, Europe, and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 19: World 10-Year Perspective for Nanodevices/Tools by Geographic Region - Percentage Breakdown of Revenues for USA, Japan, Europe, and Rest of World for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

III. MARKET

1. The United States

A.Market Analysis

Outlook

Industry Overview

Public Sector Funding

Major Nanobiotechnology Institutions and Centers

The Nanobiotechnology Center (NBTC)

Principal NBTC Partners

Centre for Biologic Nanotechnology (CBN)

Centre for Biological and Environmental Nanotechnology(CBEN)

Regulatory Environment

Technological Developments

Product Introductions/Developments

Strategic Corporate Developments

Key Players

B.Market Analytics

Table 20: US Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 21: US 10-Year Perspective for Nanobiotechnology by Technology Segment -Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

2. Japan

A.Market Analysis

Outlook

Public Sector Funding

Technological Development

B.Market Analytics

Table 22: Japanese Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 23: Japanese 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

3. Europe

A.Market Analysis

Outlook

Market Overview

European Union Banks Heavily on Nanobiotechnology

Nano2Life Network

Major Nanobiotechnology Networks in Europe

Public Sector Funding

Table 24: European Nanobiotechnology Market (2003 & 2004): Percentage Breakdown of Public Sector Funding by Leading Region/Country - European Commission, Germany, France, UK, and Others (includes corresponding Graph/Chart)

Regulatory Environment

Registration for Novel Nanobiotech Drugs Pose Major Bottlenecks

Focus on Select Markets

Germany

France

United Kingdom

Rest of Europe

Ireland

Market Overview

Key Research Institutions/Centers in Nanobiotechnology

The Tyndall National Institute

The Centre for Research on Adaptive Nanostructures and NanoDevices

The National Centre for Sensor Research

The Sami Nasr Institute for Advanced Materials Science

Technological Developments

Strategic Corporate Developments

Key Players

B.Market Analytics

Table 25: European Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 26: European 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/ Tools for Years 2000, 2005 & 2010 (includes corresponding Graph/Chart)

4. Rest of World

A.Market Analysis

Outlook

Public Sector Funding

Table 27: Nanobiotechnology Market in Rest of World (2004): Percentage Breakdown of Public Sector Funding by Leading Country - South Korea, Taiwan, China, Australia, Canada, and Others (includes corresponding Graph/Chart)

Focus on Select Markets

Australia

Market Overview

Innovative Drug Delivery - A Key Focus Area for Major Australian Companies

Nanobiotechnology Offers Major Breakthrough in HIV Drug Development

Major Institution

India

Market Overview

Korea

Market Overview

Table 28: Korean Nanobiotechnology Market (2003 & 2004): Funding in US$ Million by Major Organization Type - University Centers, Public Research Institution, and Companies (includes corresponding Graph/Chart)

Key Players

B.Market Analytics

Table 29: Rest of World Recent Past, Current & Future Analysis for Nanobiotechnology by Technology Segment - Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2000 through 2010 (includes corresponding Graph/Chart)

Table 30: Rest of World 10-Year Perspective for Nanobiotechnology by Technology Segment - Percentage Breakdown of Revenues for Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, Nanotubes and Fullerenes, Other Nanomaterials) and Nanodevices/Tools for Years 2000, 2005 & 2010. (includes corresponding Graph/Chart)

IV. COMPETITION

1. Abraxis Bioscience, Inc. (USA)

Table 31: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 32: First Quarter Sales Analysis by Product: 2005-2006 (Q1) (In US$ million)

Table 33: Annual Sales Analysis: 2003-2005 (In US$ million)

Abraxis Oncology (USA)

2. Acrongenomics, Inc. (Canada)

3. Ademtech SA (France)

4. Adnavance Technologies, Inc. (Canada)

5. Advanced Micro/Nano Devices Lab (Canada)

6. Advion Biosciences, Inc. (USA)

7. Albany Molecular Research, Inc. (USA)

Table 34: Annual Sales Analysis: 2003-2005 (In US$ million)

8. Alnis Biosciences, Inc. (USA)

9. Ambri Limited (Australia)

Table 35: Half Yearly Sales Analysis: 2005-2006 (H1) (In A$ million)

Table 36: Annual Sales Analysis: 2004-2005 (In A$ million)

Table 37: Annual Sales Analysis: 2003-2004 (In A$ million)

10. Angstrom Medica, Inc. (USA)

11. ANP Technologies, Inc. (USA)

12. Arrowhead Research Corporation (USA)

Calando Pharmaceuticals, Inc. (USA)

13. Asklepios Biopharmaceutical, Inc. (USA)

14. BioDelivery Sciences International (USA)

Table 38: Annual Sales Analysis: 2004-2005 (In US$ million)

15. BioForce Nanosciences, Inc. (USA)

16. BioNano International Singapore Pte., Ltd. (Singapore)

17. Biophage Pharma, Inc. (Canada)

18. Biosante Pharmaceuticals, Inc. (USA)

Table 39: Annual Sales Analysis: 2003-2005 (In US$ thousand)

Table 40: Annual Sales Analysis by Quarter: 2004-2005 (In US$ thousand)

19. Biotrove, Inc. (USA)

20. Biovail Corporation (Canada)

Table 41: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 42: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 43: Annual Sales Analysis by Operation: 2004-2005 (In US$ million)

Table 44: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 45: Annual Sales Analysis by Operation: 2003-2004 (In US$ million)

Table 46: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

21. Capsulution Nanoscience AG (Germany)

22. Carbon Nanotechnologies, Inc. (USA)

C Sixty, Inc. (USA)

23. Cogent Systems, Inc. (USA)

Table 47: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 48: First Quarter Sales Analysis by Geographic Region: 2005-2006 (Q1) (In US$ million)

Table 49: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 50: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 51: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

24. Competitive Technologies, Inc. (USA)

Table 52: Half Yearly Sales Analysis: 2005-2006 (H1) (In US$ million)

Half Yearly Sales Analysis by Quarter: 2005-2006 (H1) (In US$ million)

Table 53: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 54: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 55: Quarterly Sales Analysis: 2003-2004 (In US$ million)

25. Concentris GmbH (Switzerland)

26. Crystalplex Corporation (USA)

27. CytImmune Science, Inc. (USA)

28. Cytoplex Biosciences (USA)

29. Debiopharm SA (Switzerland)

30. Dendritech, Inc. (USA)

31. Dendritic Nanotechnologies, Inc. (USA)

32. Do-Coop Technologies Ltd. (Israel)

33. Dow Nanotechnology (USA)

34. Ebara Corporation (Japan)

Table 56: Annual Sales Analysis: 2003-2005 (In ¥ billion)

Table 57: Annual Sales Analysis by Segment: 2004-2005 (In ¥ billion)

Table 58: Annual Sales Analysis by Geographic Region: 2004-2005 (In ¥ billion)

Table 59: Annual Sales Analysis by Segment: 2003-2004 (In ¥ billion)

Table 60: Annual Sales Analysis by Geographic Region: 2003-2004 (In ¥ billion)

35. Eiffel Technologies Ltd. (Australia)

Table 61: Annual Sales Analysis: 2003-2005 (In US$ million)

36. Elan Corporation PLC (Ireland)

Table 62: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 63: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 64: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 65: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 66: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)

Table 67: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

Elan Pharmaceuticals (USA)

37. Evident Technologies (USA)

38. Exqor (USA)

39. Flamel Technologies SA (France)

Table 68: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 69: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 70: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

Table 71: Annual Sales Analysis by Quarter: 2003-2004 (In US$ million)

40. Fluidigm Corporation (USA)

41. Genefluidics, Inc. (USA)

42. Genencor International, Inc. (USA)

Table 72: Annual Sales Analysis: 2003-2004 (In US$ million)

Table 73: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)

Table 74: Quarterly Sales Analysis: 2003-2004 (In US$ million)

43. Georgia Tech Research Corporation (USA)

44. Imedd, Inc. (USA)

45. Integrated Nano-Technologies (USA)

46. Interdisciplinary Research Collaboration In Bionanotechnology (IRC) (UK)

47. Invitrogen Corporation (USA)

Table 75: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 76: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 77: Annual Sales Analysis by Quarter: 2004-2005 (In US$ million)

48. JPK Instruments AG (Germany)

49. Kereos, Inc. (USA)

50. Luna Innovations, Inc. (USA)

51. MagnaMedics GmbH

52. Merck & Co., Inc. (USA)

Table 78: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 79: First Quarter Sales Analysis by Product: 2005-2006 (Q1) (In US$ million)

Table 80: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 81: Annual Sales Analysis by Product: 2004-2005 (In US$ million)

Table 82: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 83: Annual Sales Analysis by Product: 2003-2004 (In US$ million)

Table 84: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

53. MFIC Corporation (USA)

Table 85: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 86: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 87: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 88: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

Table 89: Quarterly Sales Analysis: 2003-2004 (In US$ million)

54. Nabsys, Inc. (USA)

55. Nacbo (Italy)

56. Nano Interface Technology, Inc. (NITI) (USA)

57. NanoBioMagnetics, Inc. (USA)

58. NanoBioNexus (USA)

59. Nanobiosym, Inc. (USA)

60. Nano-C, Inc. (USA)

61. NanoCarrier Co., Ltd. (Japan)

62. Nanocyl SA (Belgium)

63. Nanodisc, Inc. (USA)

64. Nanodynamics, Inc. (USA)

65. NanoLab, Inc. (USA)

66. Nanolab Systems Ltd. (Finland)

67. Nanolight Technologies (USA)

68. Nanologix, Inc. (USA)

69. NanoNord A/S (Denmark)

70. Nanophase Technologies Corporation (USA)

Table 90: First Quarter Sales Analysis: 2005-2006 (Three Months Ended, March) (In US$ millions)

Table 91: First Quarter Sales Analysis By Operations: 2005-2006 (Three Months Ended, March) (In US$ millions)

Table 92: Annual Sales Analysis: 2003-2005 (In US$ millions)

Table 93: Annual Sales Analysis By Operations: 2004- 2005 (In US$ millions)

Table 94: Annual Sales Analysis By Operations: 2003- 2004 (In US$ millions)

Table 95: Quarterly Sales Analysis: 2004-2005 (In US$ millions)

Table 96: Quarterly Sales Analysis: 2003-2004 (In US$ millions)

71. Nanoplex Technologies, Inc. (USA)

72. Nanoprobes, Inc. (USA)

73. Nanosolutions GmbH (Germany)

74. Nanospectra Biosciences, Inc. (USA)

75. Nanosphere, Inc. (USA)

76. Nanosys, Inc. (USA)

77. Nanotherapeutics, Inc. (USA)

78. Nanoxis AB (Sweden)

79. National Physical Laboratory (UK)

80. Platypus Technologies, LLC (USA)

81. Proteinx Lab (USA)

82. PSiVida Ltd. (Australia)

83. Sigma-Aldrich Corporation (USA)

Table 97: First Quarter Sales Analysis: 2005-2006 (Q1) (In US$ million)

Table 98: Annual Sales Analysis: 2003-2005 (In US$ million)

Table 99: Quarterly Sales Analysis: 2004-2005 (In US$ million)

Table 100: Annual Sales Analysis by Segment: 2004-2005 (In US$ million)

Table 101: Annual Sales Analysis by Geographic Region: 2004-2005 (In US$ million)

Table 102: Quarterly Sales Analysis: 2003-2004 (In US$ million)

Table 103: Annual Sales Analysis by Segment: 2003-2004 (In US$ million)

Table 104: Annual Sales Analysis by Geographic Region: 2003-2004 (In US$ million)

84. SRU Biosystems, Inc. (USA)

85. Starpharma Holdings Limited (Australia)

Table 105: Half Yearly Sales Analysis: 2005-2006 (H1) (In A$ million)

Table 106: Annual Sales Analysis: 2003-2005 (In A$ million)

Table 107: Annual Sales Analysis by Segment: 2004-2005 (In A$ million)

Table 108: Annual Sales Analysis by Segment: 2003-2004 (In A$ million)

86. Tap Pharmaceutical Products, Inc. (USA)

87. Triton Biosystems, Inc. (USA)

88. U.S. Genomics, Inc. (USA)

89. Visigen Biotechnologies, Inc. (USA)

90. Vulvox Nano/Biotechnology Corporation (USA)

91. Xoma Ltd. (USA)

Table 109: Annual Sales Analysis: 2004-2005 (In US$ thousand)

Table 110: Annual Sales Analysis by Segment: 2004-2005 (In US$ thousand)

Table 111: Annual Sales Analysis by Geographical Region: 2004-2005 (In US$ thousand)

Abstract

This report analyzes the worldwide markets for Nanobiotechnology in US$ Million. The major product segments analyzed are Nanomaterials (Solid Inorganic Nanoparticles, Nanocomposites, Nanostructured Materials & Membranes, and Nanotubes and Fullerenes), and Nanodevices/Tools. The report provides separate comprehensive analytics for the US, Japan, Europe, and Rest of World. Annual forecasts are provided for each region for the period of 2000 through 2010. The report profiles 91 companies including many key and niche players worldwide such as Alnis Biosciences, Inc., American Pharmaceutical Partners, Inc., Biosante Phosphate Pharmaceuticals, Inc., Capsulution NanoScience AG, Carbon Nanotechnologies, Inc, C Sixty, Inc, Dendritic Nanotechnologies, Inc., Dendritech, Inc, Elan Pharmaceuticals, Flamel Technologies, Inc, iMedd, Inc., Nanospectra Biosciences, Inc., Nanophase Technologies Corporation, Nano-C, Inc., Nanocyl SA, Nanolab Systems Ltd, Nanosphere, Inc., Nanotherapeutics, Inc., Nanosys, Inc., PSiVida Ltd, Quantum Dot Corp, Starpharma Holdings Ltd, Sigma Aldrich Company, and Triton Biosystems, Inc.

Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location. Adobe Acrobat Reader 7.0 is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Titles available via "online download" are not affected by this and are still delivered to your reading room immediately.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Get Full Details About This Report >>

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.